BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 1845119)

  • 1. Development of BCG as a live recombinant vector system: potential use as an HIV vaccine.
    Fuerst TR; Stover CK; de la Cruz VF
    Biotechnol Ther; 1991; 2(1-2):159-78. PubMed ID: 1845119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New use of BCG for recombinant vaccines.
    Stover CK; de la Cruz VF; Fuerst TR; Burlein JE; Benson LA; Bennett LT; Bansal GP; Young JF; Lee MH; Hatfull GF
    Nature; 1991 Jun; 351(6326):456-60. PubMed ID: 1904554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines.
    Aldovini A; Young RA
    Nature; 1991 Jun; 351(6326):479-82. PubMed ID: 2046750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of cell-mediated immune response in mice by whole HIV-1 gag in Mycobacterium bovis BCG as a live vaccine candidate.
    Promkhatkaew D; Pinyosukhee N; Thongdeejaroen W; Sutthent R; Sawanpanyalert P; Warachit P
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):113-22. PubMed ID: 19323043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective immunity elicited by rBCG vaccines.
    Stover CK; Bansal GP; Langerman S; Hanson MS
    Dev Biol Stand; 1994; 82():163-70. PubMed ID: 7958471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Mycobacterium bovis BCG.
    Bastos RG; Borsuk S; Seixas FK; Dellagostin OA
    Vaccine; 2009 Nov; 27(47):6495-503. PubMed ID: 19720367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant BCG as an antigen delivery system.
    Flynn JL
    Cell Mol Biol (Noisy-le-grand); 1994; 40 Suppl 1():31-6. PubMed ID: 7950859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
    Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards new mycobacterial vaccines.
    Gicquel B
    Dev Biol Stand; 1994; 82():171-8. PubMed ID: 7958472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
    Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
    Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella.
    Berggren RE; Wunderlich A; Ziegler E; Schleicher M; Duke RC; Looney D; Fang FC
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):489-95. PubMed ID: 8548327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team
    J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W; Ren L; Jin N
    J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral response and genetic stability of recombinant BCG expressing hepatitis B surface antigens.
    Rezende CA; De Moraes MT; De Souza Matos DC; McIntoch D; Armoa GR
    J Virol Methods; 2005 Apr; 125(1):1-9. PubMed ID: 15737410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.
    Kanekiyo M; Matsuo K; Hamatake M; Hamano T; Ohsu T; Matsumoto S; Yamada T; Yamazaki S; Hasegawa A; Yamamoto N; Honda M
    J Virol; 2005 Jul; 79(14):8716-23. PubMed ID: 15994765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.
    Joseph J; Saubi N; Pezzat E; Gatell JM
    Expert Rev Vaccines; 2006 Dec; 5(6):827-38. PubMed ID: 17184220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and immunogenicity of recombinant Mycobacterium bovis Bacillus Calmette-Guérin strains secreting the antigen ESAT-6 from Mycobacterium tuberculosis in mice.
    Wang LM; Shi CH; Fan XL; Xue Y; Bai YL; Xu ZK
    Chin Med J (Engl); 2007 Jul; 120(14):1220-5. PubMed ID: 17697571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of recombinant BCG expressing rotavirus VP6 as an anti-rotavirus vaccine.
    Dennehy M; Bourn W; Steele D; Williamson AL
    Vaccine; 2007 May; 25(18):3646-57. PubMed ID: 17339069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.